{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-034326","form_type":"8-K","ticker":"AMIX","cik":"0001617867","company_name":"Autonomix Medical, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.999534+00:00","generated_at":"2026-05-30T01:57:46.714660+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Autonomix Q2 FY2025 net loss $2.8M; PoC trial shows 100% of lead-in patients off opioids at 4-6 weeks","bullets":["Net loss of $2.8M for three months ended Sept 30, 2024 vs $6.0M loss same quarter last year; cash $5.2M.","100% of lead-in responders zero opioid use at 4-6 weeks post-procedure; 83% pain reduction at follow-up.","60% enrollment reached in pancreatic cancer pain PoC trial; 79% responder rate with zero opioid use at 7 days.","Upcoming milestones: complete enrollment Q4 CY2024, topline data 1H 2025, FDA clearance targeted 1H 2027.","R&D expense $1.2M (vs $0.5M YoY) driven by clinical trial and product development costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-034326","json":"https://secwatch.observer/filing/0001437749-24-034326.json","markdown":"https://secwatch.observer/filing/0001437749-24-034326.md","text":"https://secwatch.observer/filing/0001437749-24-034326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1617867/000143774924034326/0001437749-24-034326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1617867/000143774924034326/amix20241107_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:57:46.714660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}